Oncology · 9 h ago
Neuroendocrine differentiation linked to HER2-therapy escape in breast cancer
A study in Cancer Discovery reports neuroendocrine features in 22% of progressive breast cancer cases, predominantly but not exclusively in HER2-positive disease. Patient-derived organoid and xenograft models were used to investigate this cell-state change and its potential role in treatment resistance.
- Neuroendocrine features emerged or increased in 22% of progressive cases.
- Cases were predominantly, but not exclusively, HER2-positive.
- NCAM-positive cells may evade EpCAM-based circulating tumor cell detection.
- FGFR1 dependency was identified in neuroendocrine tumor models.
Neuroendocrine differentiation has been associated with treatment resistance in prostate and lung cancers. In this study, researchers examined progressive breast cancer cases and used patient-derived epithelial and neuroendocrine organoid and xenograft models to investigate neuroendocrine differentiation (NED), its molecular features, and possible treatment vulnerabilities.
Neuroendocrine features emerged or increased in 22% of progressive cases, predominantly, but not exclusively, in HER2-positive breast cancer. The investigators report epigenetic silencing of EpCAM and amplified HER2 during NED, with NEUROD1 acting as a key regulator of the neuroendocrine cell state. NCAM-positive putative circulating tumor cells were detected in patients whose cells had not been detected using EpCAM-based methods. The neuroendocrine tumor cells also showed an FGFR1 dependency associated with NCAM–FGFR1 interaction and mesenchymal FGFR1 splicing.
The findings identify NED as a potential route of escape from HER2-targeted therapy and suggest implications for tumor monitoring and intervention. However, the supplied abstract does not give the number of patient cases, clinical outcomes, or evidence that targeting FGFR1 improves outcomes; the proposed monitoring and treatment implications therefore require further validation.
In practice
For patients with progressive breast cancer, especially HER2-positive disease, the findings suggest neuroendocrine differentiation may be one mechanism of treatment escape. The reported 22% refers to progressive cases, but the abstract does not state the cohort size or establish how often this occurs in broader practice. NCAM-based detection and FGFR1 targeting are potential research directions, not validated monitoring or treatment strategies; the supplied evidence does not show that changing therapy based on these findings improves outcomes.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Cancer Discovery: Neuroendocrine Differentiation Mediates Escape from HER2-Targeted Therapy in Breast Cancer ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.